JATT · JATT II Acquisition Corp.

JATT II Acquisition Corp represents the second SPAC vehicle for Dr. Someit Sidhu’s team, building on the success of JATT I, which raised $138M in 2021 and merged with Zura Bio in 2023 despite 99% redemptions leaving just $13M for the target. This $60M IPO (upsizable to $69M) targets healthcare/biotech, emphasizing data-driven approaches like machine learning and computational biology. The sponsor’s 1.725M founder shares (20% post-IPO) were acquired for $25K ($0.014/share), creating immediate 23%+ dilution at $10/share trust value but strong sponsor alignment. Management’s track record—Sidhu’s serial biotech entrepreneurship (Izana to Roivant, Khanda Therapeutics) and Fernandez’s finance background—positions it competitively in life sciences deal flow, though CFIUS risks from Sidhu’s UK citizenship may constrain US targets. No warrants in this unitless structure reduces complexity but limits upside leverage. Trust proceeds ($60M) provide ~$58M for acquisition after fees, targeting enterprise values exceeding net proceeds. Redemption mechanics allow full liquidity at ~$10/share, with 20% group limit but no overall cap, risking deal failure if redemptions exceed minimum cash conditions. Prior SPAC’s heavy redemptions highlight execution risk, yet Zura’s post-merger $641M valuation validates the thesis. Governance features independent directors with VC/biotech pedigrees (Goyal, Kluft, Staral, Badial) and CFIUS disclosure. Overall, strong team continuity but execution hinges on sourcing amid SPAC fatigue and regulatory hurdles.